Press Releases

Press Releases

Samsung Biologics named a Fortune Future 50 company

Samsung Biologics named a Fortune Future 50 company

 

  - Boston Consulting Group and Fortune examined 1,100 publicly traded companies in 12 months
   - Alphabet, Netflix, Alibaba Group Holdings were also listed in ‘Fortune Future 50’
   - Continue to satisfy not only customers but also patients through innovation in health care

 

 

2018. 10. 19 (Friday)

 

 

Samsung Biologics plants complete view from top 

 

Incheon, South Korea, October 19, 2018- Samsung Biologics, a global leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO) based in South Korea, announced today that it has been ranked on Fortune’s Future 50 list of companies best positioned for strong future growth and breakout growth.

 

The Fortune, in partnership with Boston Consulting Group, created ‘Future 50’ in 2017 and ranked 50 global companies with the best prospects for long-term growth.

 

The result is a composite of scores in four dimensions: Strategy, Technology and Investments, People, and Structure.

 

Alphabet, Netflix, Alibaba Group Holdings were also listed in ‘Fortune Future 50’ along with Samsung Biologics.

 

Dr. T.H Kim, the president and CEO of Samsung Biologics, said “Positioned on ‘Fortune Future 50’ proves Samsung Biologics’ growth potential once again just in 7 years” and he added “Samsung Biologics will continue to make the full efforts to grow into a world leading biopharmaceutical drug development and manufacturing company that can help not only our customers but also our patients through continuous innovation and global market development.” 

 

On the other hand, Samsung Biologics’ Plant 3 became CGMP ready in October 1st, 2018. Although the company is only seven years old, it became the world’s largest CMO with total bioreactor capacity of 362,000 liters in Plant 1, 2, and 3.

 

In addition, Samsung Biologics has secured CDMO contracts with 24 companies for 33 products and received 19 global manufacturing approvals as of the end of September.

 

 

- The End-

 

 

 

Samsung Biologics named a Fortune Future 50 company

 

  - Boston Consulting Group and Fortune examined 1,100 publicly traded companies in 12 months
   - Alphabet, Netflix, Alibaba Group Holdings were also listed in ‘Fortune Future 50’ 
   - Continue to satisfy not only customers but also patients through innovation in health care

 

 

2018. 10. 19 (Friday)

 

 

Samsung Biologics plants complete view from top 

 

Incheon, South Korea, October 19, 2018- Samsung Biologics, a global leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO) based in South Korea, announced today that it has been ranked on Fortune’s Future 50 list of companies best positioned for strong future growth and breakout growth.

 

The Fortune, in partnership with Boston Consulting Group, created ‘Future 50’ in 2017 and ranked 50 global companies with the best prospects for long-term growth.

 

The result is a composite of scores in four dimensions: Strategy, Technology and Investments, People, and Structure.

 

Alphabet, Netflix, Alibaba Group Holdings were also listed in ‘Fortune Future 50’ along with Samsung Biologics.

 

Dr. T.H Kim, the president and CEO of Samsung Biologics, said “Positioned on ‘Fortune Future 50’ proves Samsung Biologics’ growth potential once again just in 7 years” and he added “Samsung Biologics will continue to make the full efforts to grow into a world leading biopharmaceutical drug development and manufacturing company that can help not only our customers but also our patients through continuous innovation and global market development.” 

 

On the other hand, Samsung Biologics’ Plant 3 became CGMP ready in October 1st, 2018. Although the company is only seven years old, it became the world’s largest CMO with total bioreactor capacity of 362,000 liters in Plant 1, 2, and 3.

 

In addition, Samsung Biologics has secured CDMO contracts with 24 companies for 33 products and received 19 global manufacturing approvals as of the end of September.

 

 

- The End-

 

 

 

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION